Introduction: Lung cancer remains the leading cause of cancer death among all cancers. The discovery of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations led to an increased survival rate in patients with locally advanced and metastatic non-small cell lung cancer (NSCLC). Results of the ALTA 1L study showed superior outcomes for patients treated with brigatinib compared to patients treated with crizotinib.Background: We conducted research including 23 patients with ALK-positive lung adenocarcinoma who were treated with brigatinib in first or further lines of therapy. The median follow-up was 22 months (4–66 months).Results: There were no significant differences in patient population between the first and further lines of treatment regarding sex distribution (p= 0.692), smoking status (p= 0.554), ECOG performance status (p= 1.000), and baseline presence of brain metastases (p= 0.862). The response rate was 47.8%, and disease control was 95.6%. The 12-month progression-free survival (PFS) and overall survival (OS) rates were 85.3% and 86.5%, respectively, while the 60-month PFS rate was not reached, and the 60-month OS rate was 27.1%. The mPFS and mOS were 32 months.Conclusions:The results of this analysis are promising, as our patients experienced better outcomes compared to those in the ALTA 1L study, which may be attributed to the small sample size. However, the effectiveness of brigatinib has been confirmed in our clinical practice.
引言：在所有癌症中，肺癌仍是癌症死亡的首要原因。表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）突变的发现，使得局部晚期和转移性非小细胞肺癌（NSCLC）患者的生存率有所提高。ALTA 1L研究结果显示，与接受克唑替尼治疗的患者相比，接受布格替尼治疗的患者具有更优的临床结局。 背景：本研究纳入了23例ALK阳性肺腺癌患者，这些患者在一线或后续治疗中接受了布格替尼治疗。中位随访时间为22个月（范围4-66个月）。 结果：在一线治疗与后续治疗的患者群体中，性别分布（p=0.692）、吸烟状况（p=0.554）、ECOG体能状态评分（p=1.000）以及基线脑转移情况（p=0.862）均无显著差异。客观缓解率为47.8%，疾病控制率达95.6%。12个月无进展生存（PFS）率和总生存（OS）率分别为85.3%和86.5%，而60个月PFS率尚未达到，60个月OS率为27.1%。中位无进展生存期（mPFS）与中位总生存期（mOS）均为32个月。 结论：本分析结果显示出积极前景，与ALTA 1L研究数据相比，本研究患者获得了更好的临床结局，这可能与样本量较小有关。尽管如此，布格替尼的疗效在我们的临床实践中已得到证实。
肿瘤(癌症)患者之家